The mono- Mannich bases 3-(t- butylamino )methyl-4?-chloro-, 3-(4- benzylpiperidin-1-yl)methyl-4′-chloro-, 3-(4-benzylpiperazin-1- yl )methyl-4′-chloro-, 4′-chloro-3-diethylaminomethyl-, 4′-chloro-3-(pyrrolidin-1-yl)methyl-, 4′-chloro-3-(piperidin-1-yl)methyl- and 4′-chloro-3-(3- and 4- methylpiperidin-1-yl)methyl-5-[7-bromo (and 7- trifluoromethyl )-1,5-naphthyridin-4-ylamino]- biphenyl-2-ol, and the corresponding substituted 5-(7-trifluoromethylquinazolin-4-ylamino)bi- phenyl-2-ols, have been prepared by condensation of the 5-amino-3-(N- substituted aminomethyl )-4′-chlorobiphenyl-2-ols and the appropriate 4-chloro heterocycle. The antimalarial activity of these products against the chloroquine-sensitive isolate (FCQ-27) of Plasmodium falciparum revealed that the 1,5-naphthyridines reported here were less active than the corresponding di-Mannich bases, e.g. (6), derived from 4-[7- bromo (and 7-trifluoromethyl)-1?,5′-naphthyridin-4′-ylamino]phenol, a feature not shared by the corresponding quinazolines.
单曼尼希碱 3-(叔丁基
氨基)甲基-4?-
氯-,3-(
4-苄基哌啶-1-基)甲基-4′-
氯-,3-(4-苄基
哌嗪-1-基)甲基-4′-
氯-,4′-
氯-3-
二乙基氨基甲基-、4′-
氯-3-(
吡咯烷-1-基)甲基、4′-
氯-3-(
哌啶-1-基)甲基和 4′-
氯-3-(3-和
4-甲基哌啶-1-基)甲基-5-[7-
溴(和 7-三
氟甲基)-1、5-
氨基-3-(N-取代的
氨基甲基)-4′-
氯联苯-2-醇和相应的取代的 5-(7-三
氟甲基
喹唑啉-4-基
氨基)
联苯-2-醇,是通过 5-
氨基-3-(N-取代的
氨基甲基)-4′-
氯联苯-2-醇和适当的 4-
氯杂环缩合制备的。这些产品对
氯喹敏感的恶性疟原虫分离物(F
CQ-27)的抗疟活性表明,这里报告的
1,5-萘啶类化合物的活性低于相应的二曼尼希碱,例如从(6)和(7)中提取的二曼尼希碱。例如由 4-[7-
溴(和 7-三
氟甲基)-1?,5′-
萘啶-4′-基
氨基]
苯酚衍生的 (6),相应的
喹唑啉类不具有这种特征。